Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $26.3750.

A number of brokerages have recently commented on KURA. Lake Street Capital initiated coverage on Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price on the stock. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. UBS Group reissued a “buy” rating and issued a $15.00 price target (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Tuesday.

Insider Activity

In related news, SVP Thomas James Doyle sold 7,142 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the sale, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 8,180 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $69,202.80. Following the sale, the insider owned 267,274 shares in the company, valued at approximately $2,261,138.04. This represents a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 36,068 shares of company stock valued at $305,135. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently modified their holdings of the business. IFP Advisors Inc boosted its position in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares in the last quarter. Allworth Financial LP increased its position in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after buying an additional 3,769 shares during the period. Finally, Merit Financial Group LLC purchased a new position in shares of Kura Oncology during the 3rd quarter valued at approximately $89,000.

Kura Oncology Trading Down 2.7%

NASDAQ KURA opened at $9.27 on Friday. The company has a market capitalization of $822.81 million, a PE ratio of -2.92 and a beta of 0.25. The company has a fifty day moving average of $8.68 and a 200 day moving average of $9.52. Kura Oncology has a 1 year low of $5.45 and a 1 year high of $12.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.06 and a quick ratio of 6.05.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The company had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%. Research analysts forecast that Kura Oncology will post -3.36 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.